Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.

Pediatric blood & cancer - 1 Dec 2020

Paramathas Sangeetha, Guha Tanya, Pugh Trevor J, Malkin David, Villani Anita

Abstract excerpt

Liquid biopsy, specifically circulating tumor DNA (ctDNA) detection, has started to revolutionize the clinical management of patients with cancer by surpassing many limitations of traditional tissue biopsies, particularly for serial testing. ctDNA sequencing has been successfully utilized for cancer detection, prognostication, and assessment of disease response and evolution. While the applications of ctDNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Early Detection of Cancer

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Neoplastic Cells, Circulating

Share to Neoplastic Syndromes, Hereditary

Share to Prognosis

Source

Identifiers

PMID: 33047872
DOI: 10.1002/pbc.28758

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Considerations for the use of circulating tumor DNA sequencing as a screening tool in cancer predisposition syndromes.PMID 33047872Read ↗

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.Semantic proximity Read ↗

The feasibility of using mutation detection in ctDNA to assess tumor dynamics.Semantic proximity Read ↗

Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer DetectionSemantic proximity Read ↗

Genetic profiling of cancer with circulating tumor DNA analysis.Semantic proximity Read ↗

Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications.Semantic proximity Read ↗

A clinician's handbook for using ctDNA throughout the patient journey.Semantic proximity Read ↗

Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and ScreeningSemantic proximity Read ↗

Liquid Biopsy: Approaches to Dynamic Genotyping in CancerSemantic proximity Read ↗

Circulating tumor DNA-From bench to bedside.Semantic proximity Read ↗

Toward liquid biopsies in cancer treatment: application of circulating tumor DNASemantic proximity Read ↗

Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.Semantic proximity Read ↗

Identification of Germline Cancer Predisposition Variants During Clinical Ctdna TestingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.